Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented EQRx in the transaction. EQRx announced a strategic drug creation, development, and commercialization collaboration with Aurigene Discovery Technologies Limited to develop drug...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx in the deal while Wilson Sonsini Goodrich & Rosati represented InSilico. EQRx annlounced a strategic collaboration with Insilico Medicine to jointly...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx in the deal. EQRx announced a strategic collaboration with Abdul Latif Jameel Health, part of the international diversified family business of...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx in the deal. EQRx announced a partnership to leverage Germany-based Evotec’s data-driven integrated drug discovery and development platform across different drug...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx on the deal. EQRx announced a strategic drug discovery and development partnership to use Absci’s artificial intelligence and synthetic biology platform...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx on the deal. EQRx closed a strategic drug creation, development, and commercialization collaboration with Exscientia. The collaboration combines Exscientia’s leading AI-driven drug...
You must be a Standard 1 Year member to access this content.
